to a glycine-to-serine substitution 24 . Genomic DNA sequencing confirmed the specific FBN1 mutations ( Fig. 1a and Supplementary  Fig. 1a ). We established two subclonal hiPSC lines for each MFS line. Three wild-type (WT) hiPSC lines from healthy individuals were used as controls (Supplementary Table 1) , and all results represent the average of these three lines (WT).
We confirmed that hiPSC lines expressed the human pluripotency-associated gene products and that they were karyotypically normal ( Fig. 1b and Supplementary Fig. 1b-d) . MFS hiPSC pluripotency was assessed by differentiation into all three embryonic germ layers ( Supplementary Fig. 1e,f) and by teratoma formation in vivo (Supplementary Fig. 1g ).
hiPSCs were then differentiated into the three embryonic origin-specific SMC lineages as previously described 21, 25 ( Fig. 1c and Supplementary Fig. 2a,b) . The SMCs were then passaged and matured in 10% serum-containing medium for periods ranging from 1 to 3 months (stage S30). Neuroectoderm was generated as described previously 26 and then trypsinized to single cells and passaged up to 12 times to generate neural crest-like (NC) cells (unpublished data). Similarly to the mesoderm intermediates, NC cells were differentiated to SMCs and allowed to mature in serumcontaining medium (Supplementary Fig. 2 ). The intermediate populations were characterized for expression of specific markers of lateral mesoderm (LM), paraxial mesoderm (PM) and NC cells at both the mRNA and protein levels ( Supplementary Fig. 2a,b) . In response to TGF-β1 and platelet derived growth factor type B homodimer (PDGF-BB) treatment, the expression of these intermediate markers was downregulated, whereas the levels of SMC markers, including CNN1 and MYH11, increased (Supplementary Fig. 2a ).
Abnormal fibrillin-1 deposition and increased TGF-b
After 1 month in serum-containing medium, extracellular fibrillin-1 deposition appeared irregular and less abundant in MF C1242Y LM-, PM-and NC-derived SMCs (below, LM-SMCs, PM-SMCs and NC-SMCs, respectively) than in equivalent WT SMC subtypes, as assessed by immunofluorescence (Fig. 1d) . Abnormal organization of fibrillin-rich microfibrils in MF C1242Y ECM was confirmed by transmission electron microscopy ( Fig. 1e and Supplementary Fig. 3 ). Fibrillin-1 immunostaining showed that the abnormal microfibril phenotype was more severe in MF C1242Y NC-SMCs than in LM-or PM-SMCs (Fig. 1f) . A similar phenotype was observed for MF G880S NC-SMCs ( Supplementary Fig. 4a,b) . These results suggest that NC-SMCs are more affected by alterations in fibrilllin-1. This is largely consistent with the clinical distribution of aneurysms, which occur preferentially in the aortic root, ascending aorta and arch, regions populated predominantly by NC-SMCs. Notably, neither FBN1 mutation affected fibrillin-1 synthesis (Supplementary Fig. 4c,d) .
In MFS, abnormal fibrillin-1 may lead to excessive release of TGF-β from the ECM 9 . Accordingly, we measured TGF-β1 in WT and MF C1242Y SMC supernatants by ELISA. We observed higher TGF-β1 levels in all MF C1242Y SMC populations than in WT, and this increase was greatest in the supernatant of MF C1242Y NC-SMCs (Fig. 1g) . Equally, MF G880S NC-SMCs also showed higher TGF-β1 levels ( Supplementary Fig. 4e ).
Consistent with these observations, the amount of TGF-β1 protein extracted from SMCs and the extracellular matrix was higher in MF C1242Y and MF G880S NC-SMCs than in those from WT and the LM-and PM-SMC lineages (Fig. 1h) . TGF-β1 mRNA levels did not substantially differ between WT and MF SMC lineages, suggesting that increased protein levels were due to increased accumulation in the ECM (Supplementary Fig. 4f ). We observed increased mRNA levels of plasminogen activator inhibitor-1 (PAI-1, encoded by SERPINE1), a known target of TGF-β1 signaling 27 , and of a range of matrix metalloproteinases (MMPs) in MF C1242Y SMCs, especially the NC-derived subtype (Fig. 1i,j) . Data supporting higher TGF-β1 activity in MF C1242Y and MF G880S NC-SMCs were obtained by measuring the luciferase signal in mink lung epithelial cells stably transfected with human PAI-1 luciferase reporter and incubated with NC-SMCconditioned medium (Supplementary Fig. 4g ).
MF C1242Y NC-SMCs recapitulate the MFS aortic phenotype
Our MFS-hiPSC-derived SMC model enables us to observe changes in NC-SMC phenotype from an early developmental stage (here termed PTD12) to a more mature stage (S30), which may reflect disease progression in MFS patients 28 .
We observed morphological differences between WT and MF C1242Y NC-SMCs after prolonged culture in serum-containing medium (S30), with WT NC-SMCs appearing spindle-shaped and MF C1242Y NC-SMCs appearing larger and more stellate (Fig. 2a) . mRNA analysis showed increased expression of smooth muscle markers in MF C1242Y NC-SMCs at S30 versus WT NC-SMCs (Fig. 2a,b) . Furthermore, the proliferative capacity of both MF C1242Y NC-SMC clones decreased dramatically during maturation, compared with WT ( Fig. 2c,d ). Similar morphology and behavior was observed in MF G880S NC-SMCs ( Supplementary  Fig. 5a,b) . Moreover, MF C1242Y NC-SMCs showed higher poly-caspase activity at an early stage (PTD12), whereas at a more mature stage, NC-SMCs from both MFS lines showed a higher incidence of cell death than did WT NC-SMCs, consistent with increased SMC loss in MFS aortic dilatation ( Fig. 2e and Supplementary Fig. 5c ).
MF C1242Y NC-SMCs demonstrated reduced contractility in response to stimulation with the cholinergic agent carbachol (Fig. 2f,h) . The intracellular calcium responses of WT and both lines of MFS NC-SMCs were also different: WT NC-SMCs generated robust cyclic calcium waves, whereas MFS NC-SMCs showed equivalent initial calcium release upon carbachol treatment but did not generate propagating calcium waves and returned abruptly to basal levels (Fig. 2g,i,  Supplementary Fig. 5d and Supplementary Videos 1 and 2) . Similar contraction and Ca 2+ flux abnormalities were previously seen in the C1039G mouse MFS model 29, 30 . Together these observations indicate that MFS NC-SMCs show functional changes typical of those observed in the aortas of patients with MFS 31, 32 .
TGF-b signaling and cyclic stretching in MF C1242Y model
The C1039G MFS mouse model has implicated both TGF-β canonical and noncanonical (ERK-mediated) signaling pathways in contributing to the progress of the Marfan phenotype 11 . We used our in vitro human model to dissect TGF-β pathways at early and mature stages. We observed that levels of phosphorylated SMAD2 (P-SMAD2), a TGF-β canonical signaling component, and noncanonical components such as P-ERK1/2 and P-p38, were increased in MF C1242Y and MF G880S NC-SMCs at PTD12 stage compared to WT, whereas no differences were detected between WT and MFS fibroblast lines (Fig. 3a,b and Supplementary Fig. 6a ). At stage S30, the increase in P-ERK1/2 levels was no longer detectable, whereas P-p38 and P-SMAD2 levels remained elevated (Fig. 3b) . These findings are consistent with recent observations of developmental-stage-dependent differences in signaling in the MFS mouse 15 .
When we looked at the transcriptional levels of MMPs, which are downstream targets of TGF-β signaling, we observed that WT and MFS fibroblast lines did not show significant differences ( Supplementary  Fig. 6b ), whereas MMP expression levels were increased in both MFS NC-SMC mutants at PTD12 (Supplementary Fig. 6c ) and at S30
A r t i c l e s (Fig. 3c) . The tissue-specific inhibitors of MMPs (TIMPs) showed a biphasic expression pattern, with increased expression at an early stage ( Supplementary Fig. 6d ) but lower expression than WT at S30 (Fig. 3d) , suggesting increasing proteolysis with prolonged culture.
To confirm increased MMP activity in the MFS NC-SMCs at S30, we also performed a FITC-gelatin degradation experiment, which showed extensive proteolytic activity in MFS NC-SMCs compared to the WT (Fig. 3e,f and Supplementary Fig. 6e ). 
MF

SMC cyclic stretch exacerbates the MFS phenotype
WT and MFS SMCs were mechanically stretched for 24 h using 10% cyclic stretching at 1 Hz to mimic aortic hemodynamic forces. After 24 h, both WT and MF C1242Y NC-SMCs were aligned parallel to the direction of the stretch (Fig. 4a) . Smooth muscle markers showed increased expression in MF C1242Y NC-SMCs (Fig. 4b) . MMP9 and MMP10 expression was significantly increased in MF C1242Y NC-SMCs in response to stretching (Fig. 4c) . Furthermore, we observed that collagen type I (COL-1, encoded by COL1A1) expression and deposition were higher in MFS NC-SMCs than in WT cells and further increased upon stretching (Fig. 4d,e) , which may lead to greater stiffness of the ECM 33 . Moreover, we observed increased binding of phalloidin-FITC and immunostaining for vinculin in MF C1242Y SMCs in static conditions compared to WT, which were both further increased after stretching, suggesting that MF C1242Y SMCs have higher density of stress fibers (phalloidin) and focal adhesions (vinculin) than WT SMCs ( Fig. 4f-h ).
We also observed higher expression of p38, at the mRNA and protein levels, in MF C1242Y SMCs in response to cyclic stretch ( Fig. 4i,j) .
Effect of general TGF-b inhibition on the MFS phenotype
To test whether TGF-β signaling may have different roles at different stages of NC-SMC development, we treated both WT and MF C1242Y NC-SMCs with a blocking antibody against TGF-β (anti-TGF-β) and losartan, a specific AGTR1 blocker (Supplementary Fig. 7a ).
Both treatments promoted fibrillin-1 accumulation in mature (S30) MF C1242Y NC-SMCs (Fig. 5a,b) , and this was associated with reduced canonical TGF-β activity, as measured by transfecting a 4× Smad binding element (SBE4) promoter-luciferase reporter in both WT and MF C1242Y NC-SMCs (Fig. 5c) . Moreover, anti-TGF-β and losartan treatments were both able to efficiently downregulate expression of MMPs and upregulate TIMP3 in mature cells (S30; Fig. 5d ) and at early stages (PTD12, Supplementary Fig. 7b ). We therefore propose that excessive TGF-β activity, through effects on MMP and TIMP expression, is at least partly responsible for the reduced amount of fibrillin-1 in MFS NC-SMCs. Notably, losartan was more effective in reducing ECM degradation than doxycycline (dox), a nonspecific inhibitor of MMPs, suggesting that losartan may be acting through additional mechanisms beyond simple MMP inhibition (Supplementary Fig. 7c,d ). Extracellular fibrillin-1 abundance was only partially restored after dox treatment, suggesting that the changes we observed resulted from abnormalities in both degradation and deposition and that mutant fibrillin-1 may be more prone to proteolytic degradation than the WT protein ( Supplementary  Fig. 7e,f) . High TGF-β1 levels are likely to be caused by ECM breakdown, as it decreases upon dox treatment (Supplementary Fig. 7g ).
Despite beneficial effects on fibrillin-1 deposition and matrix proteolysis, anti-TGF-β treatment did not rescue the impaired proliferation of MF C1242Y NC-SMCs, whereas losartan provided partial rescue (Fig. 5e) . 
A r t i c l e s
Furthermore, the increased apoptosis seen in MF C1242Y NC-SMCs was unaffected by losartan treatment, as assessed by Annexin V analysis (Fig. 5f) . Likewise, a poly-caspase assay also showed no benefit with losartan treatment for MF C1242Y NC-SMC cell death (Supplementary Fig. 8a ).
Taken together, these results suggest that ECM turnover in MFS is regulated through pathways that are distinct from those regulating SMC proliferation and death.
Emerging roles of p38, KLF4 and b 1 integrin in the MFS model
To better understand the contribution of different TGF-β signaling pathways in the development of the MFS phenotype, we treated NC-SMCs with inhibitors of the canonical pathway (SB431542), ERK1/2 phosphorylation (PD98059) or p38 MAP kinase (SB203580) (Fig. 6 and Supplementary Fig. 9a,b) . Analysis of fibrillin-1 deposition by immunostaining showed that inhibition of p38 phosphorylation rescued the phenotype comparably to losartan in both MF C1242Y and MF G880S NC-SMCs (Fig. 6a,b and Supplementary Fig. 10a,b) , whereas inhibition of canonical Smad signaling or ERK1/2 by SB431542 or PD98059, respectively, had no significant effects (Fig. 6a,b and Supplementary Fig. 10a,b) . Similar results were found for effects on cell proliferation, with significant rescue of proliferation only with SB203580 and losartan (Fig. 6c) .
To investigate further the proliferative mechanisms affected in MFS NC-SMCs, we looked at potential regulators including KLF4 and observed a dramatic increase in KLF4 mRNA expression in MFS lines compared to WT NC-SMCs ( Fig. 6d and Supplementary  Fig. 11a ). Inhibition of p38 upon SB203580 treatment or efficient knockdown of KLF4 using siRNA (siRKLF4) increased mRNA levels of the proliferation marker CCND1, which were significantly lower in MF C1242Y than in WT NC-SMCs (Fig. 6e) . Moreover, both TP53 (encoding p53) and CDKN1A (encoding p21), which promote cell cycle arrest, were upregulated in MFS cells and reduced in response to SB203580 or siRKLF4 treatment (Fig. 6f,g ). Therefore, silencing KLF4 has a positive effect on proliferation in MF C1242Y and MF G880S NC-SMCs (Supplementary Fig. 11b,c) . Moreover, silencing of KLF4 increased the deposition of fibrillin-1 in the matrix compared to cell treated with control scramble siRNA (Fig. 6h,i) .
Similarly to KLF4 knockdown, treatment with BIX02189, a specific inhibitor of the MEK5-ERK5 pathway, reduced KLF4 mRNA and protein expression in MF C1242Y NC-SMCs (Fig. 6j and Supplementary  Fig. 11d) . Conversely, SB203580 and losartan did not affect total KLF4 mRNA or protein expression, suggesting that p38 and KLF4 contribute independently to the signaling pathway that controls SMC proliferation ( Fig. 6j and Supplementary Fig. 11d) . Consequently, inhibiting the MEK5-ERK5 pathway by BIX02189 restored proliferation A r t i c l e s rate and mRNA expression for TP53, CCND1 and CDKN1A in MF C1242Y NC-SMCs to levels comparable to that of WT cells ( Fig. 6c and Supplementary Fig. 11e ).
Notably, SB203580 and siRKLF4 reduced apoptotic activity in both MFS mutant lines (Fig. 7a and Supplementary Fig. 10d ). This may indicate that p38 and KLF4 contribute to the same regulatory apoptotic mechanism, and that this mechanism is exclusive to SMCs, as no difference in cell death was seen between WT and MFS fibroblasts (Supplementary Fig. 10c ). Apoptosis levels in MF C1242Y NC-SMCs were unchanged or increased upon losartan, PD98059 or U0126 (selective inhibitor of MEK1/2) treatments, respectively, suggesting that the ERK1/2-mediated pathway has a protective role against cell death in this model ( Fig. 7a and  Supplementary Fig. 12a ).
Before stretching
After stretching Moreover, MFS NC-SMC apoptosis was substantially reduced in cells with plasminogen activation, suggesting that pericellular proteolysis is partially responsible for MFS SMC death 34 ( Supplementary  Fig. 12b) .
Last, the stretch studies provided new insight about MFS cell death mechanisms. Upon cyclic stretching, MF C1242Y NC-SMCs expressed higher levels of KLF4, CDKN1A and TP53, which may contribute to MFS apoptosis (Fig. 7b) . In addition, mRNA and protein expression of β 1 integrin, an essential adhesion molecule, increased in response to cyclic stretch (Fig. 7c,d) . A β 1 integrin-blocking antibody specifically downregulated P-p38 levels and, consequently, TP53 expression (Fig. 7e,f) . The hypothesis that β 1 integrin may have an apoptosispromoting role potentially mediated by p38 in MFS NC-SMCs is consistent with results from Annexin V staining that showed decreased apoptotic levels in MFS NC-SMCs upon blockade by anti-β 1 integrin (Fig. 7g) . Furthermore, because β 1 integrin was more highly expressed in NC-SMCs than in the other lineages, these findings may explain why NC-SMCs are more vulnerable to fibrillin-1 alterations (Supplementary Fig. 13a,b) .
Correction of C1242Y mutation by CRISPR-Cas9 FBN1 editing
The upregulation of both P-p38 and KLF4 observed in our hiPSCderived MF C1242Y NC-SMC model was also found in aortic sections from two patients affected by Marfan syndrome, as compared to healthy individuals, validating our in vitro findings (Fig. 8a-d) .
To verify that the MFS phenotype in MF C1242Y hiPSC-derived SMCs is caused solely by the C1242Y substitution, we generated a CRISPR-Cas9 isogenic MFS-hiPSC line (CRISPR-MF corrected) in which the nucleotides in the mutant allele were replaced with WT nucleotides (Supplementary Fig. 14a,b) . In parallel, we generated as control an isogenic CRISPR-Cas9 MFS-hiPSC line in which the WT nucleotides were inserted in the WT allele, thereby retaining the C1242Y alteration (CRISPR-MF mutant) ( Supplementary  Fig. 14b-d) . CRISPR-MF corrected cells showed fibrillin-1 phenotypes similar to WT cells, in contrast to MF C1242Y and CRISPR-MF mutant cells (Fig. 8e,f) . In CRISPR-MF corrected NC-SMCs, abundance of phosphorylated TGF-β pathway effectors was lowered to levels comparable to that of WT (Fig. 8g) . In addition, TGF-β levels in supernatant, mRNA expression of MMP10 and the extent of matrix degradation in CRISPR-MF corrected NC-SMCs were significantly reduced ( Fig. 8h and Supplementary Fig. 15a-f) .
In conclusion, our hiPSC-derived SMCs are a model for MFS and a tool for the identification of new targets, including p38 and KLF4, which may represent novel therapeutic opportunities for MFS treatment (Fig. 8i) .
DISCUSSION
This study describes an MFS patient-derived hiPSC model that faithfully mimics the human vascular phenotype, which is the main cause of premature death in MFS 7 . Recently, Quarto et al. 35 described the MFS skeletal phenotype using a hiPSC model. However, our model recapitulates the key aspects of MFS vascular pathology and highlights the complexity of the downstream signaling pathways, identifying a key role for p38 and KLF4 in disease development.
A crucial step in these studies was the generation of vascular SMCs of specific embryonic origins to model different aortic regions, as aneurysms in MFS are found principally in the aortic root, ascending aorta and arch-regions populated by NC-SMCs 36, 37 . Our model indicates that NC-SMCs, which deposit larger amounts of extracellular fibrillin-1 (Fig. 2a,b ) and appear to be more proliferative than the other two lineages, are most severely affected by the disease. Thus, NC-SMCs appear to possess intrinsic properties-such as differential expression of β 1 integrin-that make them more susceptible to FBN1 mutations, reinforcing the importance of using lineage-specific systems for vascular disease modeling.
Abnormal TGF-β activation and signaling has been documented in MFS mouse models 12, 19, 38 and has been proposed as a common factor in MFS-related disorders, such as Loeys-Dietz syndrome [39] [40] [41] . As TGF-β bioavailability seems to be affected by inhibition of MMP activity via dox, we suggest that increased proteolysis is responsible for high TGF-β levels detected in our MFS model 42 . Importantly, blocking TGF-β, whether by TGF-β-neutralizing antibody or losartan, attenuated or prevented aortic root dilatation in mice 43 . However, recent randomized clinical trials in patients with MFS have been disappointing, with losartan showing no benefit over either placebo or beta-blockade 16, 44, 45 .
The rationale for using losartan as a TGF-β blocker is that angiotensin II can regulate TGF-β1 mRNA and protein expression and, potentially, TGF-β activation 46, 47 and cross-talk with TGF-β signaling by promoting the phosphorylation of MAP kinases 48 .
Interestingly, in C1039G MFS mice, TGF-β-mediated Erk1/2 activation drives aneurysm formation 19 . However, other studies have shown that TGF-β neutralization either exacerbates or mitigates TAA progression, depending on whether the treatment is initiated before or after aneurysm formation 15, 49 . Indeed, dual treatment with losartan and late TGF-β blockade entirely blocks aortic aneurysm development in mgR mice and leads to dramatic increases in P-Erk1/2 (ref. 15 ). These findings suggest that the link between P-ERK1/2 and disease development is not simple. Interestingly, p38 activation has been documented in Fbn1-null (mgN) mice with a more severe aortic phenotype 50 , and systemic p38 blockade has been found to normalize P-Smad2 levels in the mgN mouse.
We demonstrated that increased TGF-β activity in MFS SMCs was associated with increased phosphorylation of endogenous SMAD2, ERK1/2 and p38 at an early stage, as reported in MFS mouse models 19, 50 , whereas at a more mature stage, P-ERK1/2 was reduced to WT levels, which may indicate the need for distinct therapies at different disease time points, as also suggested by Ramirez and colleagues using the mgR mouse model 15 .
In our model, as consequence of reducing TGF-β activity, losartan was able to lower MMP expression and reduce ECM degradation when cells were treated both at PTD12 and S30 stages. However, losartan had minimal or no effect in reducing apoptotic activity in MFS SMCs (Fig. 5f) .
By dissecting TGF-β pathways using both canonical and noncanonical pathway inhibitors, we observed that blocking ERK1/2 aggravated the phenotype by reducing MFS-SMC proliferation and increasing apoptotic rates. Conversely, p38 inhibition by SB203580 had beneficial effects on MF C1242Y SMC proliferative ability and viability. The improved SMC viability was associated with upregulation of proliferation markers and downregulation of TP53 and CDKN1A, known to inhibit the cell cycle with a role in apoptosis 51, 52 . Taken together, these data suggest that in this human system, elements of TGF-β noncanonical signaling such as p38 may, depending on the disease stage, have a detrimental impact, whereas others, such as ERK1/2, may have a protective role in MFS pathogenesis 15 .
Consequently, broad upstream inhibition of TGF-β signaling may not fully reverse the MFS phenotype, and targeting of regulatory pathways such as p38 and the identification of novel targets such as KLF4 (refs. 53,54) may be essential. In response to cyclic stretch, we observed a more severe MFS phenotype in SMCs, including upregulation of MMPs and p38, increased COL-1 deposition and higher densities of stress fibers and focal adhesions, resembling the elevated cellular and ECM stiffness seen in SMCs from patients with MFS 33 . These observations indicate a complexity of signaling that may reflect additional non-TGF-β-mediated mechanotransduction caused by defective fibrillin-1 as a major contributor to the phenotype 55, 56 and uncover β 1 integrin as a potential mediator of this process.
Our findings suggest that β 1 integrin, which is known to interact with fibrillin-1 (ref. 57) , appears to have an important role in regulation of MFS SMC death, potentially through p38, as shown previously 58 , and may explain the susceptibility of the ascending and aortic arch to aneurysm development, as it is highly expressed in NC-SMCs.
Finally, the results obtained with our MFS-hiPSC-derived SMC in vitro model, including high levels of KLF4 and P-p38, were validated in patient samples, suggesting that the in vitro system accurately models human disease.
In conclusion, our model represents a tool to dissect molecular and mechanosensing mechanisms of MFS and identify novel targets for potential treatments, as well as a resourceful platform for testing new drugs. Our human lineage-specific SMC model has opened the door for the use of hiPSCs harboring different FBN1 mutations to understand the mechanisms underlying genotype-phenotype variability in MFS, which will allow the development of preventive strategies and precision medicine for individual patients.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of the paper. PBS, fixed with 4% PFA for 15 min, washed with PBS and permeabilized using a blocking buffer (0.5% Triton X-100) for 1 h at room temperature. Incubation with primary anti-vinculin antibody (1:100; Sigma-Aldrich) overnight at 4 °C was followed by incubations with Alexa Fluor-tagged 568 and CytoPainter phalloidin-iFluor 488 (1:200; Abcam) and DAPI for 1 h at room temperature. Membranes were washed three times with PBS for 5 min and mounted using ProLong Gold (Thermo Fisher).
TGF-b-neutralizing antibody and inhibitor treatment. SMCs at stage PTD12 or S30 (1-month culture in serum-containing medium), were treated for 1 week with different inhibitors, which are listed in Supplementary  Table 5 . Samples were processed for fibrillin-1 immunostaining analysis and RT-PCR analysis as described above.
KLF4 siRNA gene silencing. KLF4 knockdown was carried out using KLF4 Silencer Select from Ambion (siRKLF4; ID517793). A nonspecific siRNA (siScr; AllStars Negative control, Qiagen) was used as a negative control. hiPSC-derived SMCs were transfected with siRNA (20 nM per well of a 6-well plate) using DharmaFECT transfection reagent (Thermo Scientific Dharmacon). The transfection was repeated after 2 d, and the mRNA and protein analyses were done after 24 h and 48 h, respectively. The efficiency of KLF4 knockdown by siRNA was approximately 90% (Fig. 6d) .
